ArticleFrontiers in neuroinformatics2020
ANSH: Multimodal Neuroimaging Database Including MR Spectroscopic Data From Each Continent to Advance Alzheimer's Disease Research.
Article in Frontiers in neuroinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide. The etiology of AD is not known, and intense research involving multimodal neuroimaging data (e.g., MRI, functional MRI, PET etc.) is extensively used to identify the causal molecular process for AD. In this context, various imaging-based databases accessible to researchers globally, are useful for an independent analysis. Apart from MRI-based brain imaging data, the neurochemical data using magnetic resonance spectroscopy (MRS) provide early molecular processes before the structural or functional changes are manifested. The existing imaging-based databases in AD lack the integration of MRS modality and, thus, limits the availability of neurochemical information to the AD research community. This perspective is an initiative to bring attention to the development of the neuroimaging database, "ANSH," that includes brain glutathione (GSH), gamma aminobutyric acid (GABA) levels, and other neurochemicals along with MRI-based information for AD, mild cognitive impairment (MCI), and healthy subjects. ANSH is supported by a JAVA-based workflow environment and python providing a simple, dynamic, and distributed platform with data security. The platform consists of two-tiered architecture for data collection and management further supporting quality control, report generation for analyzed data, and data backup with a dedicated storage system. The ANSH database aims to present a single neuroimaging data platform incorporating diverse data types from healthy control and patient groups to provide better insights pertaining to disease progression. This data management platform provides flexible data sharing across users with continuous project monitoring. The development of ANSH platform will facilitate collaborative research and multi-site data sharing across the globe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.